[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552060":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":34,"locations":41,"responsibleParty":141,"collaborators":18,"id":143,"slug":144,"hasResults":145,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":145,"sex":151,"minAge":152,"maxAge":18,"enrollmentInfo":153,"targetDuration":18,"studyType":156,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":44,"whyStopped":18,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Study therapy will include a mixed intervention by a neuropsychologist and a program based on a digital tool",[13],"Other: Cognitive Behavioral Therapy (CBT) neuropsychologist",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Usual management of the cognitive complaint according to the habits of center",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"Cognitive Behavioral Therapy (CBT) neuropsychologist","* CBT: at least 3 teleconsultations by the neuropsychologist (up to 1\u002Fweek maximum)\n* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes \u002F week",[9],[25],"digital program",[27,31],{"name":28,"affiliation":29,"role":30},"Amelie DARLIX, MD","Institut de Cancérologie de Montpellier (ICM)","STUDY_CHAIR",{"name":32,"affiliation":29,"role":33},"Estelle GUERDOUX, PHD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Aurore MOUSSION","CONTACT","467612446","+33","Aurore.Moussion@icm.unicancer.fr",[42,62,74,85,96,107,118,129],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Institut régional du Cancer de Montpellier","RECRUITING","Montpellier","Hérault","34298","France","FR",{"type":51,"coordinates":52},"Point",[53,54],3.87635,43.61093,{"lat":54,"lon":53},[57,61],{"name":58,"role":37,"phone":59,"phoneExt":39,"email":60},"Amélie DARLIX, MD","4 67 61 25 57","amelie.darlix@icm.unicancer.fr",{"name":28,"role":33,"phone":18,"phoneExt":18,"email":18},{"facility":63,"status":64,"city":65,"state":18,"zip":18,"country":48,"countryCode":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"CHU Amiens","NOT_YET_RECRUITING","Amiens",{"type":51,"coordinates":67},[68,69],2.3,49.9,{"lat":69,"lon":68},[72],{"name":73,"role":33,"phone":18,"phoneExt":18,"email":18},"Mathieu BOONE, MD",{"facility":75,"status":64,"city":76,"state":18,"zip":18,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"CHU Bordeaux","Bordeaux",{"type":51,"coordinates":78},[79,80],-0.58046,44.84124,{"lat":80,"lon":79},[83],{"name":84,"role":33,"phone":18,"phoneExt":18,"email":18},"Charlotte BRONNIMANN, MD",{"facility":86,"status":64,"city":87,"state":18,"zip":18,"country":48,"countryCode":49,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"CHU Lyon","Lyon",{"type":51,"coordinates":89},[90,91],4.84789,45.74906,{"lat":91,"lon":90},[94],{"name":95,"role":33,"phone":18,"phoneExt":18,"email":18},"François DUCRAY, MD",{"facility":97,"status":64,"city":98,"state":18,"zip":18,"country":48,"countryCode":49,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Hôpital de la Timone","Marseille",{"type":51,"coordinates":100},[101,102],5.38107,43.29695,{"lat":102,"lon":101},[105],{"name":106,"role":33,"phone":18,"phoneExt":18,"email":18},"Emeline TABOURET, MD",{"facility":108,"status":64,"city":109,"state":18,"zip":18,"country":48,"countryCode":49,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"CHU Nancy","Nancy",{"type":51,"coordinates":111},[112,113],6.18496,48.68439,{"lat":113,"lon":112},[116],{"name":117,"role":33,"phone":18,"phoneExt":18,"email":18},"Luc TAILLANDIER, MD",{"facility":119,"status":64,"city":120,"state":18,"zip":18,"country":48,"countryCode":49,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"CHU Nîmes","Nîmes",{"type":51,"coordinates":122},[123,124],4.35788,43.83665,{"lat":124,"lon":123},[127],{"name":128,"role":33,"phone":18,"phoneExt":18,"email":18},"Jean-Sébastien GUILLAMO, MD",{"facility":130,"status":64,"city":131,"state":18,"zip":132,"country":48,"countryCode":49,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Institut Claudius Régaud","Toulouse","31059",{"type":51,"coordinates":134},[135,136],1.44367,43.60426,{"lat":136,"lon":135},[139],{"name":140,"role":33,"phone":18,"phoneExt":18,"email":18},"Delphine LARRIEU-CIRON, MD",{"type":142,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100552060","efficacy-of-a-mixed-distancial-neuropsychological-rehabilitation-program-in-patients-with-grade-2-or-3-diffuse-glioma-100552060",false,"NCT06468176","Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma","Efficacy of a Mixed Distancial Neuropsychological Rehabilitation Program in Patients With Grade 2 or 3 Diffuse Glioma : a Randomized Controlled Trial","FREEDOME","Inclusion Criteria:\n\n* Age ≥18 years old, no age limit;\n* Histo-molecular diagnosis of grade 2 or 3 diffuse glioma according to World Health Organization (WHO) Classification 2016, regardless of oncological treatments previously received;\n* Patient in satisfactory general condition for the study, defined by a WHO performance index ≤ 2 (ECOG-Performance Status (PS) ≤ 2);\n* Neurosurgical excision (excluding biopsy) performed ≥ 12 months previously;\n* In the case of oncological treatment, patient who has completed his sessions (radiotherapy, chemotherapy) for ≥ 6 months;\n* Patient presenting a cognitive complaint defined as a response rated at least \"Fairly\" to at least one of the 2 items (n°20 and 25) assessing cognitive complaint in the EORTC QLQ-C30 questionnaire (i.e., defined as a score on the \"Cognitive Functioning\" scale ≤ 66.67);\n* Fluent in French;\n* Affiliation to the French Social Security System;\n* Possible regular use of a digital tool with Internet access;\n* Signature of informed consent prior to any study procedure.\n\nExclusion Criteria:\n\n* Visual or auditory deficit not corrected to normal and\u002For preventing use of computer tools (i.e., homonymous lateral hemianopia is not a criterion for non-inclusion) ;\n* Concurrent participation in a study with cognition as primary endpoint (e.g., \"POLCA\", \" POLO \" clinical trials) ;\n* Legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent form or completing the study ;\n* Unstable or uncontrolled psychiatric syndrome (i.e., psychotropic treatments are not a criterion for non-inclusion if doses are stable) ;\n* Known severe cognitive impairment (e.g., neurodegenerative disease, sequelae of head trauma, etc.) or defined by a score ≤ 20 on the MoCA test or impacting the ability to use digital tools at home ;\n* Oncological treatment (radiotherapy and\u002For chemotherapy and\u002For surgery) planned within 4 months of inclusion. Targeted anti-Isocitrate DeHydrogenase (IDH) therapies are authorized.","ALL","18 Years",{"count":154,"type":155},187,"ESTIMATED","INTERVENTIONAL",[158],"NA","Diffuse low-grade glioma are rare brain tumors affecting young subjects (median age at diagnosis 38 years for grade 2 and 49 years for grade 3). Cognitive symptoms are common in these patients, including memory, attention and executive function disorders. These disorders may have a deleterious impact on patients' professional, family and social lives, and have a negative impact on their quality of life. The benefits of cognitive rehabilitation have been demonstrated in other neurological pathologies. Furthermore, due to limited access to rehabilitation by neuropsychologists, some studies have evaluated the impact of digital cognitive rehabilitation programs. However, it cannot replace human support.",[161],"Glioma, Malignant",[163,164,165,166],"Oncology","Neurologic Disorder","Neuropsychological rehabilitation","Diffuse Glioma","2025-12-12",{"date":169,"type":170},"2025-12-19","ACTUAL",{"date":172,"type":170},"2024-07-05",{"date":174,"type":155},"2027-12-15",{"name":5,"class":6},8]